VNDA - Vanda Pharmaceuticals Inc
IEX Last Trade
5.28
0.060 1.136%
Share volume: 600,277
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$5.22
0.06
1.15%
View ratios
| Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-11-03 | 2023-02-09 | 2023-05-03 | 2023-07-28 | 2023-11-09 | 2024-02-08 | 2024-05-09 | 2024-08-01 | |
| Assets | |||||||||
| Total Assets | 621.788 M | 634.247 M | 644.532 M | 641.682 M | 641.605 M | 648.440 M | 652.682 M | 651.371 M | |
| Current Assets | 507.106 M | 519.292 M | 533.707 M | 533.504 M | 536.572 M | 432.946 M | 439.425 M | 439.180 M | |
| Inventories | 1.590 M | 1.194 M | 1.105 M | 1.080 M | 1.006 M | 1.357 M | 1.505 M | 1.469 M | |
| Other Current Assets | 21.373 M | 17.727 M | 6.593 M | 9.452 M | 16.436 M | 9.170 M | 7.065 M | 8.171 M | |
| Short Term Investments | 21.373 M | 17.727 M | 6.593 M | 9.452 M | 16.436 M | 9.170 M | 7.065 M | 8.171 M | |
| Total Receivables | 29.352 M | 33.512 M | 24.513 M | 33.621 M | 29.272 M | 34.155 M | 36.713 M | 41.864 M | |
| Current Cash | 454.791 M | 466.859 M | 501.496 M | 489.351 M | 489.858 M | 388.264 M | 394.142 M | 387.676 M | |
| Total Non-current Assets | 114.682 M | 114.955 M | 110.825 M | 108.178 M | 105.033 M | 215.494 M | 213.257 M | 212.191 M | |
| Property Plant Equipment | 2.594 M | 2.573 M | 2.333 M | 2.164 M | 2.128 M | 2.037 M | 2.306 M | 2.303 M | |
| Other Assets | 10.353 M | 11.378 M | 10.462 M | 9.948 M | 10.277 M | 9.985 M | 9.517 M | 9.355 M | |
| Intangible Assets | 18.944 M | 18.565 M | 18.186 M | 17.808 M | 17.428 M | 121.369 M | 119.351 M | 117.599 M | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 621.788 M | 634.247 M | 644.532 M | 641.682 M | 641.605 M | 648.440 M | 652.682 M | 651.371 M | |
| Total liabilities | 106.131 M | 107.049 M | 108.793 M | 101.784 M | 98.505 M | 103.530 M | 108.687 M | 108.855 M | |
| Total current liabilities | 92.623 M | 91.436 M | 93.794 M | 87.397 M | 84.837 M | 87.697 M | 93.342 M | 93.791 M | |
| Accounts Payable | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 4.605 M | 6.800 M | 6.612 M | 6.445 M | 6.196 M | 8.827 M | 8.831 M | 9.059 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 4.605 M | 6.800 M | 6.612 M | 6.445 M | 6.196 M | 8.827 M | 8.831 M | 9.059 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 515.657 M | 527.198 M | 535.739 M | 539.898 M | 543.100 M | 544.910 M | 543.995 M | 542.516 M | |
| Common stock | 56.575 M | 56.659 M | 57.011 M | 57.454 M | 57.519 M | 57.540 M | 57.761 M | 58.221 M | |
| Retained earnings | -164.762 M | -157.901 M | -154.649 M | -153.129 M | -152.992 M | -155.392 M | -159.538 M | -164.056 M |